(+/-)-2-Phenyl-valeriansaeure-chlorid | 40327-98-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (+/-)-2-Phenyl-valeriansaeure-chlorid
• 英文别名: α-n-Propyl-phenylacetylchlorid；2-phenyl-valeryl chloride；(+/-)-2-phenyl-valeric acid-chloride；I+/--Propylbenzeneacetyl chloride；2-phenylpentanoyl chloride
• CAS: 40327-98-8
• 化学式: C₁₁H₁₃ClO
• 分子量: 196.677
• InChiKey: SSSJDWWXONCODH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (+/-)-2-Phenyl-valeriansaeure-chlorid 在 三乙胺 作用下， 反应 2.0h， 生成 2-phenylpent-1-en-1-one
  参考文献：
  名称：

  Multistep One-Pot Wittig/Nazarov Reaction for Construction of Cyclopentenone with Diazo Compounds and Acid Chlorides

  摘要：

  A facile multistep one-pot synthesis of single or fused cyclopentenones has been developed. The sequence involves a transition metal-catalyzed ylide formation/Wittig Olefination/Nazarov Cyclization.

  DOI：

  10.1021/ol901086f
• 作为产物：
  描述：

  (RS)-2-phenylpentanoic acid 在 氯化亚砜 作用下， 生成 (+/-)-2-Phenyl-valeriansaeure-chlorid
  参考文献：
  名称：

  使用高价碘（lambda5）试剂结合四乙基溴化铵，将α，α-二取代的乙酰胺氧化转化为相应的一碳短酮。

  摘要：

  当与高价碘（lambda（5））试剂与四乙基溴化铵（TEAB）组合在各种溶剂中反应时，α，α-二取代的乙酰胺会经历氧化脱卤素反应，生成一个碳短的酮。在进一步的研究中，一种高价碘（lambda（5））试剂，邻碘氧苯甲酸和TEAB的组合已被确立为一种新型，温和，有效和通用的转化方法。

  DOI：

  10.1021/jo801580g

文献信息

• [EN] LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS<br/>[FR] COMPOSÉS LACTAMES EN TANT QU'AGONISTES SÉLECTIFS DU RÉCEPTEUR EP4 POUR L'UTILISATION DANS LE TRAITEMENT DE MALADIES ET D'ÉTATS À MÉDIATION PAR EP4
  申请人：CAYMAN CHEMICAL CO INC

  公开号：WO2014144610A1

  公开（公告）日：2014-09-18

  Disclosed herein are compounds of formula (I) wherein L1, L2, L3, R1, R4, R5, and R6 are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, osteoporosis, bone fracture, periodontal bone loss, orthopedic implant, alopecia, neuropathic pain, and related disorders. Pharmaceutical compositions and methods of treating conditions or disorders are also described.

  披露了公式(I)的化合物，其中L1、L2、L3、R1、R4、R5和R6如说明书定义。公式(I)的化合物是EP4激动剂，可用于治疗青光眼、骨质疏松症、骨折、牙周骨丢失、骨科植入物、脱发、神经性疼痛及相关疾病。还描述了药物组合物和治疗条件或疾病的方法。
• Substituted Heterocyclic Derivative, Preparation Method And Use Thereof
  申请人：Xiamen University

  公开号：US20170334896A1

  公开（公告）日：2017-11-23

  The invention provides a compound as shown by Formula I having an enzyme activity which can inhibit endocannabinoid hydrolases NAAA and/or FAAH, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and a preparation method and a use of the compound.

  本发明提供一种具有酶活性的化合物，其化学式如下（I），能够抑制内源性大麻素水解酶NAAA和/或FAAH，或其药学上可接受的盐、水合物或溶剂化物，以及该化合物的制备方法和用途。
• FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY
  申请人：Berni Canani Roberto

  公开号：US20110098319A1

  公开（公告）日：2011-04-28

  The invention relates to novel derivatives of short-chain fatty acids, in particular derivatives of butyric acid, useful for all the known clinical applications of the latter, which show physicochemical characteristics suitable for an easy oral administration, being devoid of the unpleasant organoleptic properties that characterize butyrate. The new compounds are amide derivatives which can be synthesized by reaction of the corresponding fatty acid halide with a naturally occurring amino acid, phenylalanine or a suitable derivative thereof, and which are in a poorly hygroscopic, easily weighable form, stable to acids and alkalis and able to release the acid at the small and large bowel level in a constant manner over time. They do not have disagreeable odors and are practically tasteless, thus allowing the manufacture of preparations for oral administration also suitable for the therapy of chronic diseases and in the pediatric field.

  本发明涉及一种新型的短链脂肪酸衍生物，特别是丁酸衍生物，适用于后者的所有已知临床应用，具有适合易于口服的物理化学特性，不具有表征丁酸的不愉快的感官特性。新的化合物是酰胺衍生物，可以通过相应的脂肪酸卤化物与天然存在的氨基酸苯丙氨酸或其适当衍生物反应合成，并且以不易吸湿，易于称重的形式存在，对酸和碱稳定，并且能够在时间上以恒定的方式释放酸到小肠和大肠水平。它们没有不愉快的气味，几乎没有味道，因此可以制备适合于口服治疗慢性疾病和儿科领域的制剂。
• Compounds having lysophosphatidic acid receptor antagonism and uses thereof
  申请人：Tanaka Motoyuki

  公开号：US20070149595A1

  公开（公告）日：2007-06-28

  The present invention relates to a compound represented by formula (I): (wherein the symbols in formula were described in the description), a salt thereof, a solvate thereof or a prodrug thereof. Since the compound of the present invention binds to and is antagonistic to an LPA receptor (particularly, EDG-2), it is useful for prevention and/or treatment of urinary system disease (prostatic hypertrophy or neurogenic bladder dysfunction disease, spinal cord neoplasm, nucleous hernia, spinal canal stenosis, diseases caused by diabetes, occlusion disease of lower urinary tract, inflammatory disease of lower urinary tract, and polyuria), carcinoma-associated disease, proliferative disease, inflammation system disease, immune system disease, disease by secretory dysfunction, brain-related disease and/or chronic disease.

  本发明涉及一种由式(I)表示的化合物：（其中式中的符号在说明中被描述），其盐，溶剂化物或前药。由于本发明的化合物与LPA受体（特别是EDG-2）结合并具有拮抗作用，因此它对预防和/或治疗泌尿系统疾病（前列腺增生或神经源性膀胱功能障碍疾病，脊髓肿瘤，核突出，脊柱管狭窄，由糖尿病引起的疾病，下尿路梗阻疾病，下尿路炎症性疾病和多尿症），癌症相关疾病，增殖性疾病，炎症系统疾病，免疫系统疾病，分泌功能障碍疾病，与大脑相关的疾病和/或慢性疾病具有用处。
• Substituted heterocyclic derivative, preparation method and use thereof
  申请人：Xiamen University

  公开号：US10174015B2

  公开（公告）日：2019-01-08

  The present invention relates to a class of substituted heterocyclic derivative and preparation method thereof. The chemical structure of the substituted heterocyclic derivate is as follows,

  本发明涉及一类取代杂环衍生物及其制备方法。取代杂环衍生物的化学结构如下、